Archives of Gynecology and Obstetrics

, Volume 298, Issue 3, pp 545–550 | Cite as

Effect of iron supplementation during early pregnancy on the development of gestational hypertension and pre-eclampsia

  • Preeyaporn JirakittidulEmail author
  • Supatra Sirichotiyakul
  • Chidchanok Ruengorn
  • Kitirat Techatraisak
  • Busaba Wiriyasirivaj
Maternal-Fetal Medicine



To investigate the association between iron supplementation during early pregnancy and the presence of de novo hypertension after 20 weeks’ gestation (either gestational hypertension or pre-eclampsia).

Study design

Retrospective cohort study.


This study retrospectively reviewed the medical records of non-anemic pregnant women who received first antenatal care at the Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand, during the June 2009–December 2010 study period. All included women had blood pressure and urine albumin level data that were recorded at each antenatal visit. The study population was divided into one of the two following groups: iron supplementation starting at gestational age (GA) < 16 weeks (study group) or GA ≥ 16 weeks (control group). A comparison of the proportion of de novo hypertension arising after 20 weeks’ gestation was then performed between groups.


Four hundred non-anemic pregnant women were included, with 200 patients allocated to each groups. The overall incidence of de novo hypertension after 20 weeks’ gestation was 10% (40/400), with significantly higher prevalence in the study group than that in the control group [13.5% (27/200) vs. 6.5% (13/200); relative risk: 2.14, 95%, CI 1.22–3.73; p = 0.008]. None of the women in this study developed anemia at time of delivery. There was no significant difference between groups for GA at delivery, birth weight, or birth asphyxia.


In our study population, iron supplementation before 16 weeks’ GA was significantly associated with increased risk of developing de novo hypertension after 20 weeks’ gestation.


Thai Iron supplementation Early pregnancy Pre-eclampsia Gestational hypertension 


Authors’ contribution

PJ: project development, data collection, data analysis, and manuscript writing. SS: project development, manuscript editing, and others (Supervisor). CR: project development and data analysis. KT: manuscript editing. BW: project development and data collection.


This was an unfunded study.

Compliance with ethical standards

Conflict of interest

All the authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and/or distribute the drugs, devices, or materials described in this report.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Hospital Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statement of human rights

The present study was the retrospective study. All data were collected from previous hospital record.

Informed consent

For this type of study formal consent for participation is not required.


  1. 1.
    Brown MA, Magee LA, Kenny LC, Anath Karumanchi S, McCarthy FP, Saito S et al (2018) The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. CrossRefPubMedGoogle Scholar
  2. 2.
    Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working G et al (2015) The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol 29(5):643–657CrossRefPubMedGoogle Scholar
  3. 3.
    Wang Y, Hao M, Sampson S, Xia J (2017) Elective delivery versus expectant management for pre-eclampsia: a meta-analysis of RCTs. Arch Gynecol Obstet 295(3):607–622CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tranquilli AL, Landi B (2010) The origin of pre-eclampsia: from decidual “hyperoxia” to late hypoxia. Med Hypotheses 75(1):38–46CrossRefPubMedGoogle Scholar
  5. 5.
    Casanueva E, Viteri FE (2003) Iron and oxidative stress in pregnancy. J Nutr 133(5 Suppl 2):1700s–1708sCrossRefPubMedGoogle Scholar
  6. 6.
    Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R (2010) Pre-eclampsia. Lancet 376(9741):631–644CrossRefPubMedGoogle Scholar
  7. 7.
    World Health Organization (2016) WHO recommendations on antenatal care for a positive pregnancy experience. World Health Organization, Geneva. Accessed 15 Jan 2017
  8. 8.
    Froessler B, Gajic T, Dekker G, Hodyl NA (2018) Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet. PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW et al (2013) Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 346:f3443CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Palma S, Perez-Iglesias R, Prieto D, Pardo R, Llorca J, Delgado-Rodriguez M (2008) Iron but not folic acid supplementation reduces the risk of low birthweight in pregnant women without anaemia: a case-control study. J Epidemiol Community Health 62(2):120–124CrossRefPubMedGoogle Scholar
  11. 11.
    Brannon PM, Taylor CL (2017) Iron supplementation during pregnancy and infancy: uncertainties and implications for research and policy. Nutrients 9(12):1327. CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Bo S, Menato G, Villois P, Gambino R, Cassader M, Cotrino I et al (2009) Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol 201(2):158e1–158e6CrossRefGoogle Scholar
  13. 13.
    Huisman A, Aarnoudse JG (1986) Increased 2nd trimester hemoglobin concentration in pregnancies later complicated by hypertension and growth retardation. Early evidence of a reduced plasma volume. Acta Obstet Gynecol Scand 65(6):605–608CrossRefPubMedGoogle Scholar
  14. 14.
    Ziaei S, Norrozi M, Faghihzadeh S, Jafarbegloo E (2007) A randomised placebo-controlled trial to determine the effect of iron supplementation on pregnancy outcome in pregnant women with haemoglobin > or = 13.2 g/dL. BJOG 114(6):684–688CrossRefPubMedGoogle Scholar
  15. 15.
    Imdad A (2012) Routine iron/folate supplementation during pregnancy: effect on maternal anaemia and birth outcomes. Paediatr Perinat Epidemiol 26(1):168–177CrossRefPubMedGoogle Scholar
  16. 16.
    Falahi E, Akbari S, Ebrahimzade F, Gargari BP (2011) Impact of prophylactic iron supplementation in healthy pregnant women on maternal iron status and birth outcome. Food Nutr Bull 32(3):213–217CrossRefPubMedGoogle Scholar
  17. 17.
    Pena-Rosas JP, De-Regil LM, Garcia-Casal MN (2015) Dowswell T (2015) Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev 7:CD004736Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
  2. 2.Department of Obstetrics and Gynecology, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  3. 3.Department of Pharmaceutical Care, Faculty of PharmacyChiang Mai UniversityChiang MaiThailand
  4. 4.Department of Obstetrics and Gynecology, Faculty of Medicine Vajira HospitalNavamindradhiraj UniversityBangkokThailand

Personalised recommendations